Otsuka Sues Zydus To Block Generic Abilify

Law360, New York (June 10, 2010, 4:36 PM EDT) -- Indian drugmaker Cadila Healthcare Ltd. and its U.S. subsidiary Zydus Pharmaceuticals USA Inc. have become the latest targets of Otsuka Pharmaceutical Co. Ltd.’s legal campaign to prevent the launch of a generic version of the company's schizophrenia drug Abilify.

The Japanese drug company filed a complaint Friday in the U.S. District Court for the District of New Jersey, saying Cadila and Zydus' collaboration on an abbreviated new drug application for the active ingredient in Abilify infringes an Otsuka patent.

The patent is for aripiprazole, which is...
To view the full article, register now.